Compare GNLN & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLN | CLDI |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.4M |
| IPO Year | 2019 | 2021 |
| Metric | GNLN | CLDI |
|---|---|---|
| Price | $3.44 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.8K | ★ 67.0K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,275,000.00 | $45,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.09 |
| 52 Week High | $7.06 | $1.93 |
| Indicator | GNLN | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 64.52 | 46.33 |
| Support Level | $3.07 | $0.15 |
| Resistance Level | $3.42 | $1.26 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 86.04 | 41.34 |
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). It serves specialty retailers, smoke shops, head shops, convenience stores, and consumers. Geographically, it operates in United States, Canada, and Europe. It derives majority revenue from the United States. Its two operating segments are: Wholesale and Distribution, which includes legacy e-commerce and drop-ship operations; and Digital Assets, which includes digital asset treasury activities including acquisition, staking and validator participation related to BERA.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.